ARAnett Rancz

Anett Rancz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anett Rancz has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and Safety of Treatments for Keloids and Hypertrophic Scars: A Systematic Review and Network Meta-analysis

    by Péter Pál, Lőrinc Frivaldszky, Anett Rancz, Péter Hegyi, Mikolt Bakony, Mohamed Abdelaziz Emam, Soma Jávor, Levente Sára, Norbert Kiss

  • Open Access

    Evidence‐based ranking of diabetes prevention in prediabetes: A comprehensive network meta‐analysis of 378 randomised controlled trials

    by Bucur Maria, Eperjesi Orsolya, Panait Robert Iulian, Topala Mihaela, Babakhani Avin Aphrodite, Rancz Anett, Kói Tamás, Fazekas Karen, Obeidat Mahmoud, Papp Renáta, et al.

    Background: Ten percent of the global population presents impaired glucose tolerance. Although numerous interventions have been investigated to prevent type 2 diabetes (T2D), their comparative effectiveness remains uncertain. In this study, we assessed and ranked current pharmacological and non‐pharmacological interventions for preventing diabetes in individuals with prediabetes. Methods: The study protocol was registered on PROSPERO (CRD42023473875). Randomised controlled trials (RCTs) reporting on adult patients with prediabetes undergoing any intervention addressing dysglycaemia were eligible. Our systematic search was conducted from database inception to 19 December 2025 in three databases (MEDLINE, Embase and Cochrane Library [CENTRAL]). Network meta‐analysis was performed using the random‐effect frequentist method. Our primary outcomes were the incidence of T2D, haemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and 2‐h glucose after the glucose oral tolerance test (2hPG) expressed as relative risk (RR) and mean difference (MD), respectively, with the corresponding 95% confidence intervals (CIs). Results: We included 378 RCTs comprising 113 122 patients. The highest risk reduction for T2D when compared with control was obtained with dual incretin‐based therapy (glucagon‐like peptide 1 [GLP‐1] and gastric inhibitory polypeptide (GIP) receptor agonists [GLP‐1 + GIP RAs]) (RR = .1, CI [.05; .21]), with GLP‐1 receptor agonists (GLP‐1 RAs) ranking second (RR = .26, CI [.19; .4]) followed closely by metformin plus intensive lifestyle intervention (ILI) (RR = .27, CI [.12; .64]). Only curcumin (MD = −.49, CI [−.70; −.28]), dual GLP‐1 + GIP RA (MD = −.46, CI [−.63; −.29]), single GLP‐1 RA (MD = −.41, CI [−.50; −.31]) and physical activity (MD = −.35, CI [−.48; −.23]) achieved >.3% HbA1c reductions after 1 year. Sulphonylureas and physical activity were most effective for the 1‐year FPG decrease, while the greatest 2hPG reduction was obtained with zinc supplementation and sulphonylureas. Conclusion: Incretin‐based therapies, particularly dual GLP‐1 + GIP RA and single GLP‐1 RA, followed by metformin together with ILI, are the most effective interventions to prevent T2D in patients with prediabetes.

  • Continuous glucose monitoring for prediabetes classification in a large real-world cohort: Comparison with HbA1c and fasting plasma glucose

    by Gabriella Rákóczi, Dávid Csányi, Roland Molontay, Gergely Agócs, Boglárka Lilla Szentes, Jimin Lee, Anett Rancz, Péter Hegyi, Emese Sipter


  • Open Access

    Risk factors for pancreatic exocrine insufficiency after acute pancreatitis: A systematic review and meta-analysis

    by Orsolya Eperjesi, Maria Bucur, Anett Rancz, Ádám Zolcsák, Marie Anne Engh, Mahmoud Obeidat, Andrea Szentesi, Péter Hegyi, Stefania Bunduc


  • Open Access

    Neoadjuvant chemotherapy enables fertility preservation without compromising oncologic outcomes in early cervical cancer ≥2 cm: A systematic review and meta-analysis

    by Ádám Vincze, Dávid Márai, Lőrinc Frivaldszky, Anett Rancz, Péter Hegyi, Nándor Ács, Ferenc Bánhidy, Márton Keszthelyi, Boglárka Lilla Szentes, Zoltán Sipos, et al.

  • Open Access

    Risk Factors for Microscopic Colitis: A Systematic Review and Meta‐Analysis

    by Anett Rancz, Brigitta Teutsch, Mahmoud Obeidat, Anna Walter, Gergő Weidinger, Bálint Erőss, Péter Hegyi, Emese Mihály

    Background: Microscopic colitis (MC) is still an underdiagnosed disease due to its primarily histological appearance. We aimed to address the scarcity and inconsistency of data on MC risk factors.Methods: Our protocol was prospectively registered in PROSPERO (CRD42022286624). We systematically searched PubMed, Embase, and Cochrane from inception to January 6, 2025. Cohort, case–control, and cross‐sectional studies were included. Controls were distinguished with or without a histopathological examination. We used the random‐effect model to calculate pooled odds ratios (ORs) with 95% confidence intervals (CIs).Results: The systematic search yielded 6493 articles, of which 45 were meta‐analyzed. We found increased odds for MC in the case of nonsteroidal anti‐inflammatory drug (NSAID) and statin use compared to histological (OR = 2.57, CI: 1.45–4.53; OR = 2.15, CI: 1.14–4.05) and random (OR = 2.56, CI: 1.13–5.79; OR = 1.84, CI: 0.58–5.80) controls. Our results did not show an association between proton pump inhibitors (PPIs) and MC, compared to histological controls (OR = 1.81, CI: 0.75–4.35), except in the case of random controls (OR = 4.31, CI: 1.66–11.20). Neither current (OR = 1.35, CI: 0.88–2.06) nor previous smoking (OR = 1.26, CI: 0.67–2.39) increased the odds of MC compared to histological controls. In contrast, the odds doubled for current smoking and slightly changed for past smoking when MC patients were compared to random controls (OR = 2.40, CI: 1.64–3.50; OR = 1.11, CI: 0.93–1.31).Conclusions: NSAID and statin treatment were associated with an increased risk for MC compared to histological controls. PPIs and smoking showed only an association with MC when random controls were used.


  • Open Access

    End-to-end anastomosis provides similar quality-of-life, compared with other reconstructive techniques six months following total mesorectal excision: Systematic review and meta-analysis

    by Sarolta Beáta Kávási, Diana - Elena Iov, Anett Rancz, Ádám Zolcsák, Dániel Sándor Veres, Katalin Lenti, Pál Miheller, Péter Hegyi, Szabolcs Ábrahám


  • Open Access

    Microscopic colitis is a risk factor for low bone density: a systematic review and meta-analysis

    by Anett Rancz, Brigitta Teutsch, Marie Anne Engh, Dániel Sándor Veres, László Földvári-Nagy, Bálint Erőss, Nóra Hosszúfalusi, Márk Félix Juhász, Péter Hegyi, Emese Mihály

    Background: Microscopic colitis (MC) is a chronic inflammatory disease of the large bowel characterized by watery diarrhea, substantially decreasing the patient’s quality of life. Scarce data suggest that MC is associated with low bone density (LBD). Objectives: We aimed to assess whether MC is a risk factor for LBD and the proportion of patients with MC having LBD. Design: A systematic review and meta-analysis of studies reporting bone density measurements in MC patients. Data Sources and Methods: We systematically searched five databases from inception to October 16, 2021 (Pubmed, Embase, Cochrane, Scopus, and Web of Science). We used the random-effect model to calculate pooled odds ratios (ORs) and pooled event rates with 95% confidence intervals (CIs). To ascertain the quality of evidence of our outcomes, we followed the recommendations of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group. Results: The systematic search yielded a total of 3046 articles. Four articles were eligible for quantitative synthesis. All of them used age- and sex-matched controls to evaluate LBD occurrence among patients with MC. The odds of having LBD were twofold increased (OR = 2.13, CI: 1.42–3.20) in the presence of MC, the odds of osteopenia occurrence were 2.4 (OR = 2.45, CI: 1.11–5.41), and of osteoporosis 1.4 (OR = 1.42, CI: 0.65–3.12). The proportion of LBD was 0.68 (CI: 0.56–0.78), osteopenia was 0.51 (CI: 0.43–0.58), and osteoporosis was 0.11 (CI: 0.07–0.16) among the MC population. Our findings’ certainty of the evidence was very low following the GRADEPro guideline. Conclusion: Our data demonstrate that MC is associated with a twofold risk for LBD. Based on our findings, we suggest screening patients for bone mineral density upon diagnosis of MC. Further prospective studies with higher patient numbers and longer follow-up periods on this topic are needed. Registration: Our protocol was prospectively registered with PROSPERO (CRD42021283392).